ABSTRACT

Objective: The present investigation demonstrates a simple, sensitive and accurate high pressure liquid chromatographic (HPLC) method for the determination of alvimopan (AMP) in rat plasma.

Methods: The chromatographic separation was achieved within 10 min by using acetonitrile: potassium dihydrogen phosphate buffer pH 3.0 adjusted with orthophosphoric acid (50:50) as mobile phase on Altima Grace Smart C-18 column (5μ; 250 × 4.6 mm) at a flow rate of 1.0 ml/min with injection volume 50 μl. The drug was extracted from plasma by liquid-liquid extraction using a mixture of methanol: acetonitrile (50:50) as a solvent. The retention times of drug and internal standard were found to be 5.17 and 6.74 min, respectively. This method was validated as per the United States Food and Drug Administration (US-FDA) guidelines.

Results: The results of the validation parameters were found to be within the acceptance limits. The method was linear in the concentration range from 5-1000 ng/ml (r²= 0.9998), and the extraction recovery was found to be 78.71±3.86% for AMP. The lower limit of quantification was found to be 5ng/ml, and the stability of recovered samples at different conditions was found to be more than 95%.

Conclusion: The developed method possess good selectivity, specificity, there was no interference found in the plasma blanks at retention times of AMP and Internal Standard (IS). We found a good correlation between the peak area and concentration of the drug under prescribed conditions. Furthermore, the method can also be used to estimate the pharmacokinetic parameters of AMP.

Keywords: Alvimopan, Liquid-liquid extraction, Method development, Matrix effect, Plasma, Recovery, Stability, Validation

INTRODUCTION

Narcotic medicines that are often used to reduce the pain caused by gastrointestinal surgery. However, these medicines can cause a variety of side effects, such as nausea, vomiting, constipation and stomach pain, which are further leads to delay recovery in patients undergoing gastrointestinal surgery. Therefore, medicines that are required to prevent the above-mentioned side effects without diminishing the pain-relieving effect of narcotic medicines. Alvimopan (AMP) (Entereg), the only drug approved by the Food and Drug Administration (FDA) for the treatment of postoperative ileus [1, 2]. This drug behaves as a peripherally acting μ-opioid antagonist. Since the AMP has limited ability to cross the blood-brain barrier, many of the undesirable side-effects of the narcotic medicines are minimized without affecting analgesia or precipitating withdrawal [3, 4]. In order to comprehend the antagonist effect of AMP further, it is imperative to determine the pharmacokinetic parameters through estimation of the AMP in plasma using simple estimation methods.

Several liquid chromatography-tandem mass spectrometric (LC-MS/MS) assay methods have been employed for the determination of various drugs in the form of single and combined dosage forms [6-9]. In general, estimation of AMP in plasma and pharmaceutical formulation has also been carried out using LC-MS/MS method. In general, this method is highly sensitive to separate and identify a multitude of compounds in low concentration in a complex mixture with little assay optimization [10, 11]. However, this method has a variety disadvantages. Specifically, it requires an experienced technician, not portable, expensive and has only moderate throughput. Therefore, it is important to develop a method, which is simple and inexpensive for the estimation of AMP in plasma for routine analysis.

The present contribution provides a simple and regular estimation method for determination of AMP in rat plasma using high-pressure liquid chromatography (HPLC). [fig. 1] gives the molecular structure of AMP. As the above-mentioned, AMP is the only narcotic antagonist approved by the FDA for the treatment of postoperative surgery of gastrointestinal. In order to estimate the pharmacokinetic parameters, we made an attempt to determine the AMP in the rat plasma using routine HPLC method.

Fig. 1: Chemical structure of 2-(((25S)-2-(((3R, 4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl)methyl)-3-phenylpropanoyl)amino)acetic acid

MATERIALS AND METHODS

Chemicals and standards

Alvimopan (AMP) procured from Aurobindo Pharma (Hyderabad, India), aceclofenac (ACF) purchased from S. L. drugs (Hyderabad,
Purified water is prepared using a Millipore direct-Q 3 water purification system. Acetonitrile and methanol of HPLC grade, potassium dihydrogen phosphate, and orthophosphoric acid were purchased from Merck Ltd. (Mumbai, India).

**Preparation of standard solutions**

Preparation of AMP standard stock solution: 50 mg of AMP was weighed accurately and dissolved in 50 ml volumetric flask and made up to mark with methanol. The stock solution was diluted with the mobile phase solution when required.

Preparation of Internal standard stock solution: 10 mg of ACF was weighed accurately dissolved in 10 ml volumetric flask and made up to mark with methanol.

Preparation of phosphate buffer: Accurately weighed 272.7 g of potassium dihydrogen orthophosphate dissolved in 1000 ml of HPLC grade water and pH adjusted to 3.0 with orthophosphoric acid and sonicated.

**Sample preparation**

A 0.25 ml aliquot of plasma sample was spiked with 25 µl of drug (AMP) and 25 µl of IS, vortexed for 5 min. Added the 2 ml of a mixture of methanol: acetonitrile (50:50), vortexed for 5 min and the mixture was centrifuged for 15 min at 5000 rpm at 20°C. The supernatant liquid was separated and evaporated under nitrogen gas at 45°C. It reconstituted the residue with 0.5 ml of mobile phase and vortexed. The sample was filtered through 0.45µ syringe filter, then, loaded the sample into auto-injector vial and 50 µl of the sample injected onto HPLC system.

**Method validation**

The validation of the developed method was carried out as per US FDA guidelines for selectivity, linearity, sensitivity, accuracy, precision, recovery and stability [12, 13].

**Selectivity**

The selectivity was studied by comparing the chromatograms of six different batches of plasma sample obtained from six independent lots of control plasma along with six extracted LQC-QC samples. The method is selective if there is no interfering peak present at the retention time of the drug or IS.

**Linearity**

A calibration curve is the relationship between instrument response and known concentrations of the drug. The series of standards were prepared by spiking the required volume of working standard to 0.25 ml of plasma to yield the concentrations of 5, 20, 50, 100, 200, 400, 500 and 1000 ng/ml. Extracted the drug from plasma and injected each sample into HPLC. The linearity graph was plotted between the peak area ratios (y-axis) of AMP to IS versus the known concentration (x-axis) of AMP in plasma.

**Limit of quantification**

The lower limit of quantification (LLOQ) is the lowest concentration giving a signal-to-noise ratio of at least 10-folds, with an accuracy of 80-120% and precision of 20% to its nominal value. This is determined by analyzing 10 times of LLOQ concentration and calculated the accuracy and precision.

**Accuracy and precision**

Intra- and inter-day accuracy and precision for this method was determined at three different concentration levels on three different days. The accuracy and precision were expressed as percentage accuracy and coefficient of variation (CV) respectively. The accuracy was calculated as follows:

\[
\text{Accuracy (\%)} = \frac{\text{concentration found}}{\text{nominal concentration}} \times 100
\]

The coefficient of variation, CV was calculated as follows:

\[
\text{CV} = \frac{\text{standard deviation}}{\text{mean}} \times 100
\]

The accuracy determined at each concentration level must be within 15% and the precision around the mean value must not exceed 15% except the LLOQ where it must be within 20% of the %CV.

**Recovery and matrix effect**

Recovery is the detector response obtained from an amount of the analyte added to and extracted from the biological matrix, compared to the detector response obtained for the true concentration of the standard. It is assessed by comparing the mean peak areas of extracted LQC, MQC and HQC samples to the one obtained after the direct injection of a solution with corresponding concentration. The recovery of the drug was calculated by using the following formula:

\[
\text{Recovery (\%)} = \frac{C}{D} \times 100
\]

Matrix effect (ME) can be expressed as the suppression or enhancement of ionization of analyte by the presence of matrix components in the biological samples; quantitatively it can be termed as matrix factor. The matrix effect was calculated by using the following formula:

\[
\text{Matrix Effect (\%)} = \frac{B}{A} \times 100
\]

In this study, the peak area of AMP obtained by direct injection of standard solution as A, the corresponding standard solution of AMP spiked after extraction into plasma, injected into HPLC, the peak area of AMP as B, standard solutions spiked in plasma before extraction and followed extraction procedure and injected into HPLC, the peak area of AMP as C. The matrix effect and extraction recovery of the IS and AMP determined according to Matuzewska, B.; K.; et al. [14].

**Hemolytic effect**

The hemolysis was investigated according to the procedure described by Nicola C Hughes et al. [15]. The LQC and HQC of analyte were spiked with plasma, and hemolysed plasma samples were extracted and analyzed. If there is less than 15% difference of analyte found in the plasma as compared to hemolysed plasma, indicates no hemolytic effect [15].

**Stability**

The stability of the drug solution was determined for short-term by keeping at room temperature (25°C) for 24h. Autosampler stability was determined by storing the samples for 22 h in the autosampler, Freeze- Thaw stability: The plasma sample spiked with drug and kept in freezer (-20°C) for 24 h and thawed (25°C) for 24h. The same procedure repeated for two more cycles then followed the extraction procedure and analyzed. Wet extract samples were processed, reconstituted and kept on the bench at room temperature and analyzed after 24h for stability. Dry extract samples were processed, after evaporation, which kept on the bench at room temperature and analyzed after 24h to check their stability. Each sample injected into HPLC and concentrations obtained were compared with the nominal values of the QC samples.

**RESULTS AND DISCUSSION**

**Method development**

**Method optimization**

The chromatographic method was optimized as a mixture of 20 mmol potassium dihydrogen phosphate buffer (pH 3.0) and acetonitrile (50:50 v/v) at a flow rate of 1 ml/min with detection wavelength of 261 nm by using Altima Grace Smart C-18 column by changing various parameters on trial and error basis. During the method optimization, water and phosphate buffer in various strengths are tried along with methanol and acetonitrile as organic solvent. The mobile phase composition of 50:50 v/v acetonitrile: buffer was given good resolution, retention times of AMP and IS with a minimal tailing factor in acceptable range. The method was optimized with the mobile phase composition of acetonitrile and phosphate buffer 50:50 (v/v). The effect of buffer strength on the determination of drug was studied by different buffer strengths (10, 20 and 50 mmol). There were no significant changes in the chromatographic response and peak shape with a change in buffer molarity. A buffer molarity of 20 mmol was selected for further analysis.
After several trials, the method was optimized as a mixture of 20 mmol potassium dihydrogen phosphate buffer (pH 3.0) and acetonitrile (50:50 v/v), at a flow rate of 1 ml/min, at 261 nm for run time 15 min. These chromatographic conditions achieved a satisfactory resolution, retention time and tailing for AMP. The [fig. 2] shows that standard chromatogram of AMP along with the internal standard (IS).

Two extraction methods were tried for sample preparation i.e. protein precipitation (PPT), liquid-liquid extraction (LLE). These methods were studied for their effect on matrix sensitivity and resolution. PPT was the least effective sample preparation technique, often resulting in significant matrix effects due to the presence of many residual matrix components. LLE provided clean extract and reproducible recovery of AMP and IS. So, liquid-liquid extraction was employed in this assay development. Several organic solvents like ethyl acetate, dichloromethane, acetonitrile, methanol, and their mixtures were tried for extraction. Finally, the mixture of methanol and acetonitrile (50:50) was found to be suitable and produced a clean chromatogram for blank plasma samples with the best recovery of ARM, also possesses least matrix effect and cost-effective. It also quickly evaporate consumes less time for extraction.

We investigated several compounds to find a suitable IS, by preparing standard reference solution containing alvimopan along with aceclofenac (ACF) and telmisartan (TEL), (which were easily available for us) in the above selected mobile phase. It was injected six times on to HPLC and observed the peak shape, response, and interference of these peaks with the analyte. TEL as internal standard produced good response but poor consistent results obtained with longer retention time. In another evaluation of ACF as internal standard produced sharp peak, no interference with analytes peak as well as reproducible results was obtained. So, ACF was employed in this study as an internal standard. Hence, ACF was selected as internal standard for this study.

System suitability
The system suitability of the method was done by working stock standard of individual drugs (AMP and IS) were injected HPLC to determine the individual retention times of drugs. Then working standard solution was injected five times and we considered relative standard deviation (RSD) for five consecutive injections ≤2, the resolution between two adjacent peaks ≥2 and tailing factor<2 acceptable values [16]. Resolution (R), relative standard deviation from five replicate injections of working standard mixture solution, tailing factor (T) and retention time drug was presented in [table 1]. System suitability test confirmed that the chromatographic system was adequate for the analysis planned to be done. Then, the method was validated for various validation parameters according to the US FDA guidelines [12, 13].

Method validation
Selectivity and specificity
The developed method was found selective for both AMP and IS, as no interference was detected at the respective retention times. The chromatogram of blank extracted from plasma and chromatogram of plasma spiked with AMP and IS at LLOQ and 200 ng/ml are shown in [fig. 2]. The specificity of the present method was established by
checking the interference of AMP retention time with that of IS. This was done by injecting six replicates of matrix blank with IS. The interference of IS retention time caused by AMP, this was done by injecting 6 replicates of medium concentration of AMP. In this study, there was no peak interference of AMP or IS retention time [fig. 2]. This clearly shows the specificity and selectivity of the method.

Carryover effect

The carryover effect of the present method was established by using six injections of plasma blank and an upper limit of quantification (ULOQ) of AMP. These samples were analyzed alternately to check any carryover in the blank sample. In this study, there were no such effects observed.

### Table 1: System suitability parameters of AMP

<table>
<thead>
<tr>
<th>Parameters</th>
<th>AMP</th>
<th>IS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retention time (min)</td>
<td>5.17±0.04</td>
<td>6.7±0.04</td>
</tr>
<tr>
<td>Tailing factor</td>
<td>1.13±0.01</td>
<td>1.2±0.01</td>
</tr>
<tr>
<td>Theoretical plates</td>
<td>5881±101</td>
<td>7414±131</td>
</tr>
<tr>
<td>Peak area</td>
<td>4991±375.8</td>
<td>4543±310</td>
</tr>
</tbody>
</table>

Note: Values are expressed in mean±SD (n=6)

### Matrix effect

The matrix effect was studied at three concentration levels (LQC, MQC, and HQC), there was no significance difference in peak area of the drug in the presence and absence of matrix ions. The matrix factor and matrix effect were found to be 0.99 and >96% [table 2]. The results of ME also found within the acceptance limits indicates there was no significant matrix effect for AMP found in this method.

### Table 2: Matrix effect (ME) on the extraction of AMP from plasma

<table>
<thead>
<tr>
<th>Standard (ng/ml)</th>
<th>MF (Matrix Factor)</th>
<th>% RSD</th>
<th>%ME</th>
</tr>
</thead>
<tbody>
<tr>
<td>LQC (15)</td>
<td>96.35±1.96</td>
<td>2.04</td>
<td>0.96</td>
</tr>
<tr>
<td>MQC (250)</td>
<td>97.88±0.99</td>
<td>1.01</td>
<td>0.98</td>
</tr>
<tr>
<td>HQC (750)</td>
<td>102.77±3.79</td>
<td>3.69</td>
<td>1.03</td>
</tr>
</tbody>
</table>

Note: Values are expressed in mean±SD, Number of the sample (n=3)

### Recovery

The extraction recovery was determined at three concentration levels (LQC, MQC, and HQC) for AMP and IS by comparing the peak area of AMP obtained by injecting the standard drug spiked with plasma followed extraction, the peak area of AMP obtained by injection standard drug of same concentration. The extraction recoveries were found to be 78.71±3.86% and 68.60±0.62% for AMP and IS respectively. The data represented in [table 3].

### Table 3: Extraction recovery of AMP and IS from rat plasma

<table>
<thead>
<tr>
<th>Drug</th>
<th>Standard (ng/ml)</th>
<th>Extracted matrix standard average peak area</th>
<th>Standard drug average Peak area</th>
<th>% Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMP</td>
<td>LQC (15)</td>
<td>6924.33±54.3</td>
<td>8441±111</td>
<td>82.03</td>
</tr>
<tr>
<td></td>
<td>MQC (250)</td>
<td>5906±118.06</td>
<td>74177±157.32</td>
<td>79.62</td>
</tr>
<tr>
<td></td>
<td>HQC (750)</td>
<td>17656±98.36</td>
<td>237902±1044</td>
<td>74.47</td>
</tr>
<tr>
<td></td>
<td>Average recovery</td>
<td></td>
<td></td>
<td>78.71±3.86</td>
</tr>
<tr>
<td>ACF (IS)</td>
<td>LQC (15)</td>
<td>45032.33±735.41</td>
<td>65674.7±391.79</td>
<td>68.56</td>
</tr>
<tr>
<td></td>
<td>MQC (250)</td>
<td>45115.3±123.33</td>
<td>65157.7±259.43</td>
<td>69.24</td>
</tr>
<tr>
<td></td>
<td>HQC (750)</td>
<td>44432.2±241.16</td>
<td>65343.7±579.23</td>
<td>67.99</td>
</tr>
<tr>
<td></td>
<td>Average Recovery</td>
<td></td>
<td></td>
<td>68.60±0.62</td>
</tr>
</tbody>
</table>

Values are expressed in mean±SD, n=6

### Linearity

The linearity of this method was evaluated by linear regression analysis, using the least square method. The peak area ratio of the drug and internal standard was used for the quantification of AMP. Calibration curves were linear in the concentration range of 5-1000 ng/ml with a correlation coefficient (r²) of 0.999 and the mean regression equation was: y=0.005x+0.082. Where y is the peak ratio and x is the plasma concentration of AMP. The linearity graph was shown in [fig. 3]. The linearity range of present method [5-1000 ng/ml] was useful for the determination of AMP in rat plasma.

### Sensitivity

The standard chromatogram of AMP at LLOQ level was presented in [fig. 2]. The lower limit of quantitation (LLOQ) was found to be 5 ng/ml. The percent accuracy of LLOQ was 94.60±7.57 % and precision denoted by %RSD was 8.00%.

### Intra-day and inter-day precision and accuracy

The intra-and inter-day precision and accuracy of this assay were determined by analyzing replicates of QC samples at three concentrations on 6 different days. The coefficients of variation for the intra-and inter-day precision were<3.03%. The intra-and inter-day accuracies were 98.28-102.99%. The low levels of coefficients of variation i.e.: 1.86%-3.03% [table 4] indicate the method is accurate and precise.

### Robustness

Robustness of the method was done by changing slight variation in the parameters like mobile phase composition, flow rate, and wavelength. Present method didn't show any significant change when the critical parameters were modified. The tailing factor of the drug was always less than 2.0 and the components were well separated under all the changes carried out. Considering the
modifications in the system suitability parameters and the specificity of the method, as well as carrying the experiment at room temperature may conclude that the method conditions were robust.

**Table 4: Intra-day and inter-day accuracy and precision of AMP in plasma**

<table>
<thead>
<tr>
<th>Stability</th>
<th>Standard (ng/ml)</th>
<th>Average practical concentration</th>
<th>Accuracy mean±SD</th>
<th>% RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intra-day (n=6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LQC (15)</td>
<td>15.45±0.38</td>
<td>102.99±2.56</td>
<td>2.49</td>
<td></td>
</tr>
<tr>
<td>MQC (250)</td>
<td>245.71±4.56</td>
<td>98.28±1.82</td>
<td>1.86</td>
<td></td>
</tr>
<tr>
<td>HQC (750)</td>
<td>752.9±22.80</td>
<td>100.39±3.04</td>
<td>3.03</td>
<td></td>
</tr>
<tr>
<td>Inter-day (n=9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LQC (15)</td>
<td>14.95±0.41</td>
<td>99.64±2.74</td>
<td>2.75</td>
<td></td>
</tr>
<tr>
<td>MQC (250)</td>
<td>248.84±5.53</td>
<td>99.54±2.21</td>
<td>2.23</td>
<td></td>
</tr>
<tr>
<td>HQC (750)</td>
<td>753.0±21.46</td>
<td>100.40±2.86</td>
<td>2.85</td>
<td></td>
</tr>
</tbody>
</table>

Note: Values are expressed in mean±SD

**Table 5: Data of different stability studies of AMP in plasma**

<table>
<thead>
<tr>
<th>Stability</th>
<th>Standard (ng/ml)</th>
<th>Average practical concentration</th>
<th>Accuracy</th>
<th>% RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Freeze and thaw stability</td>
<td>LQC (15)</td>
<td>14.67±0.33</td>
<td>97.81±2.24</td>
<td>2.29</td>
</tr>
<tr>
<td></td>
<td>MQC (250)</td>
<td>251.05±0.38</td>
<td>100.52±0.15</td>
<td>0.15</td>
</tr>
<tr>
<td></td>
<td>HQC (750)</td>
<td>747.74±27.06</td>
<td>99.70±5.61</td>
<td>3.62</td>
</tr>
<tr>
<td>Bench Top Stability</td>
<td>LQC (15)</td>
<td>14.70±0.46</td>
<td>97.98±3.08</td>
<td>3.14</td>
</tr>
<tr>
<td>(Short-term stability)</td>
<td>MQC (250)</td>
<td>249.3±1.29</td>
<td>99.7±5.52</td>
<td>0.52</td>
</tr>
<tr>
<td></td>
<td>HQC (750)</td>
<td>756.7±12.01</td>
<td>100.89±1.62</td>
<td>1.59</td>
</tr>
<tr>
<td>In-Injector Stability</td>
<td>LQC (15)</td>
<td>14.81±0.09</td>
<td>98.75±0.61</td>
<td>0.61</td>
</tr>
<tr>
<td>(Auto-sampler stability)</td>
<td>MQC (250)</td>
<td>250.65±3.08</td>
<td>100.26±1.23</td>
<td>1.23</td>
</tr>
<tr>
<td></td>
<td>HQC (750)</td>
<td>745.68±7.11</td>
<td>99.42±0.95</td>
<td>0.95</td>
</tr>
<tr>
<td>Wet extract Stability</td>
<td>LQC (15)</td>
<td>14.65±0.38</td>
<td>97.63±2.56</td>
<td>2.62</td>
</tr>
<tr>
<td></td>
<td>MQC (250)</td>
<td>250.53±8.90</td>
<td>100.21±3.56</td>
<td>3.56</td>
</tr>
<tr>
<td></td>
<td>HQC (750)</td>
<td>761.89±11.46</td>
<td>101.58±1.53</td>
<td>1.51</td>
</tr>
<tr>
<td>Dry extract Stability</td>
<td>LQC (15)</td>
<td>14.88±0.37</td>
<td>99.2±2.50</td>
<td>2.52</td>
</tr>
<tr>
<td></td>
<td>MQC (250)</td>
<td>242.82±2.47</td>
<td>97.13±0.99</td>
<td>1.02</td>
</tr>
<tr>
<td></td>
<td>HQC (750)</td>
<td>746.92±7.04</td>
<td>99.59±1.05</td>
<td>1.05</td>
</tr>
</tbody>
</table>

Note*: Actual concentration of AMP in ng/ml. Values are expressed in mean±SD, Number of samples (n=5)
CONCLUSION
The developed method possess good selectivity, specificity, there was no interference found in the plasma blanks at retention times of AMP and IS. We found a good correlation between the peak area and concentration of the drug under prescribed conditions and also the recoveries found to be 78.71% for AMP. The observation of % RSD less than 5 for both intra and inter-day measurements also indicates a high degree of precision. A linearity range from 5-1000 ng/ml for AMP, this linearity range covers all the strengths of AMP. The stability of AMP was found to be within the limits i.e. 95.39-106.79% concludes that there was no degradation of AMP and also stable in the plasma at different study conditions. The method found to be highly sensitivity (5 ng/ml), good accuracy, precision and no matrix effect on the drug economic extraction procedure will help in further studies of AMP. Hence this method can be applied for quantifying the low levels of AMP in the biological matrix without the interference of plasma components for future investigation of AMP.

ACKNOWLEDGMENT
The author is thankful to Aurabindo pharma Ltd., Hyderabad, Telangana, India for providing drugs and to Adept Pharma and Bioscience Excellence Private Limited for providing all types of facilities for the research.

AUTHORS CONTRIBUTIONS
All the authors have contributed equally

CONFLICT OF INTERESTS
The authors report no conflict of interest

REFERENCES
3. Alvimopan Product Label as approved by the FDA; 2008.